Oramed Pharmaceuticals Inc. (FRA:OJU1)

Market Cap	117.37M
Revenue (ttm)	1.70M
Net Income (ttm)	37.38M
Shares Out	n/a
EPS (ttm)	0.88
PE Ratio	3.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	984
Open	2.592
Previous Close	2.501
Day's Range	2.592 - 2.732
52-Week Range	1.744 - 2.866
Beta	n/a
RSI	74.68
Earnings Date	Mar 27, 2026

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OJU1

Financial Performance

Financial numbers in USD